Advancing ADCs: From Concept To Commercialization

By Charles Johnson, Senior Director, Commercial Development; Raphael Frey, Ph.D., Director Commercial Development; and Pierre Landais, Director of Commercial Development, DPS

With more than a dozen ADCs approved and over 200 in development, speed to the clinic and reliable commercial supply now matter as much as the molecule. Payload-linker choice sets the balance between speed and customization, and route design determines how much highly potent handling a program can avoid.

The paper also covers a 15-month DNA-to-IND timeline and manufacturing scale from lab batches to commercial volumes, including planned capacity expansion. It is written by Charles Johnson and Raphael Frey of Lonza Advanced Synthesis and Pierre Landais of Lonza Integrated Biologics.

Read the full paper for the timeline and capacity details.